No Data
No Data
Precision BioSciences Announces Its Addition to the Russell Microcap Index
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Precision BioSciences Showcases ARCUS Platform at Mitochondrial Medicine 2024
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, inclu
Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, today announced that the company w
Express News | Precision Biosciences presented new clinical safety data for Pbgene-Hbv candidate at the European Liver Research Association Conference.
Express News | Precision BioSciences Inc: Ind and/or Cta on-Track for Submission in 2024
Express News | Precision BioSciences Inc: Pbgene-Hbv Was Well Tolerated Across Multiple Administrations With No off-Target Editing Observed